Ziad Taib

Data Science & AI, BioPharmaceuticals R&D, AstraZeneca
Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in Asthma.

A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in Asthma.

Journal: American journal of respiratory and critical care medicine

Published: August 19, 2020

Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trials.

Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trials.

Journal: The Lancet. Rheumatology

Published: September 09, 2019

The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial.

The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial.

Journal: International journal of chronic obstructive pulmonary disease

Published: April 10, 2018

Efficacy and Tolerability of an Inhaled Selective Glucocorticoid Receptor Modulator - AZD5423 - in Chronic Obstructive Pulmonary Disease Patients: Phase II Study Results.

Efficacy and Tolerability of an Inhaled Selective Glucocorticoid Receptor Modulator - AZD5423 - in Chronic Obstructive Pulmonary Disease Patients: Phase II Study Results.

Journal: Basic & clinical pharmacology & toxicology

Published: December 10, 2016

COPD biomarkers as tools for decision making in early clinical drug development.

COPD biomarkers as tools for decision making in early clinical drug development.

Journal: Biomarkers in medicine

Published: April 30, 2016

Objectively identified comorbidities in COPD: impact on pulmonary rehabilitation outcomes.

Objectively identified comorbidities in COPD: impact on pulmonary rehabilitation outcomes.

Journal: The European respiratory journal

Published: January 21, 2015

Study on risk factors and phenotypes of acute exacerbations of chronic obstructive pulmonary disease in Guangzhou, China-design and baseline characteristics.

Study on risk factors and phenotypes of acute exacerbations of chronic obstructive pulmonary disease in Guangzhou, China-design and baseline characteristics.

Journal: Journal of thoracic disease

Published: November 04, 2014

Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD.

Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD.

Journal: European journal of radiology

Published: February 27, 2014

Arterial stiffness in patients with COPD: the role of systemic inflammation and the effects of pulmonary rehabilitation.

Arterial stiffness in patients with COPD: the role of systemic inflammation and the effects of pulmonary rehabilitation.

Journal: The European respiratory journal

Published: December 07, 2013

Showing 1-9 of 9

Last Updated: 09/26/2026